SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| DAMELIO FRANK A | Director | 2026-08-07 | Gift | 6650 | $0 |
| MCCALLISTER MICHAEL B | Director | 2026-06-10 | Gift | 1209 | $0 |
| Stetter Mark | Director | 2026-05-21 | Option exercise | 1572 | — |
| PARENT LOUISE M | Director | 2026-05-20 | Option exercise | 1944 | — |
| PARENT LOUISE M | Director | 2026-05-20 | Option exercise | 10186 | — |
| Bisaro Paul | Director | 2026-05-13 | Open-market buy | 2000 | $152K |
| DAMELIO FRANK A | Director | 2026-05-13 | Open-market buy | 6650 | $501K |
| MCCALLISTER MICHAEL B | Director | 2026-05-11 | Open-market buy | 3000 | $233K |
| Esch Kevin | Executive Vice President | 2026-04-30 | Option exercise | 259 | — |
| Esch Kevin | Executive Vice President | 2026-04-30 | Tax withholding | 75 | $9K |
| Sarbaugh Keith | Executive Vice President | 2026-03-31 | Option exercise | 1528 | — |
| Sarbaugh Keith | Executive Vice President | 2026-03-31 | Tax withholding | 524 | $62K |
| Norden Gregory | Director | 2026-03-09 | Gift | 1213 | $0 |
| Ashton Nicholas | Executive Vice President | 2026-02-19 | Option exercise | 750 | — |
| Ashton Nicholas | Executive Vice President | 2026-02-19 | Tax withholding | 392 | $50K |
| Bisaro Paul | Director | 2026-02-19 | Option exercise | 1619 | — |
| Brannan Jamie | Executive Vice President | 2026-02-19 | Option exercise | 1204 | — |
| Brannan Jamie | Executive Vice President | 2026-02-19 | Tax withholding | 566 | $72K |
| Broadhurst Vanessa | Director | 2026-02-19 | Option exercise | 1619 | — |
| Broadhurst Vanessa | Director | 2026-02-19 | J | 517 | $66K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
A 37% surge in unsecured debt to $9.2B, paired with new convertible-note cross-default and liquidity disclosures, materially elevates solvency risk and anchors a broad-based deterioration spanning six distinct themes. Leverage and capital-structure fragility are compounded by a 25% collapse in antibacterials revenue, escalating geopolitical/trade exposure, and substantive new operational and technology risks. The cumulative worsening — pervasive across debt, revenue, supply chain, regulatory, cybersecurity/AI, and macro dimensions — clears the major threshold.
9 company-specific · 4 common-mode
New disclosure of material liquidity risk: inability to fund convertible note conversions/repurchases could trigger cross-defaults and cascade debt acceleration, threatening solvency.
We may not have the ability to raise the funds necessary to settle conversions of our convertible senior notes in cash, or to repurchase the convertible senior notes upon a fundamental change, and…
Antibacterials revenue declined 25% ($950M to $713M), reflecting realized impact of regulatory restrictions and consumer preferences on a material revenue stream.
Restrictions and bans on the use of and/or consumer preferences regarding antibacterials in food-producing animals may become more prevalent. The issue of the potential transfer of increased…
Total unsecured debt increased 37% from $6.7B to $9.2B year-over-year, materially worsening leverage and financial risk profile.
Risks related to our indebtedness We have substantial indebtedness. We have a significant amount of indebtedness, which could materially adversely affect our operating results, financial condition…
New disclosure of convertible note conditional conversion risk. Potential cash settlement requirement and working capital reduction are material liquidity and balance-sheet concerns.
The conditional conversion feature of our convertible senior notes, if triggered, may adversely affect our financial condition and operating results. In the event the conditional conversion feature…
New convertible debt disclosure. Conversion could dilute shareholder ownership and depress stock price through share issuance or short-selling pressure.
Conversion of our convertible senior notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock. The conversion of some or all of the…
Added multi-year ERP system transition risk with specific operational hazards: business continuity disruptions, cost overruns, data migration issues, sales/manufacturing delays.
We depend on sophisticated information technology and infrastructure. We rely on the efficient and uninterrupted operation of complex information technology systems to manage our operations, to…
Added substantive new risk: post-marketing studies, public confidence erosion, vaccine skepticism, and misinformation threats to product commercialization and approval.
Our products are subject to unanticipated safety, quality or efficacy concerns. Our products generally receive regulatory approval based on data obtained in controlled clinical trials. After approval…
Added specific risks: federal workforce reductions, hiring freezes, agency reorganizations, deregulatory efforts, and operational difficulties from counterparties. Expanded PFAS scope to include packaging. Materially escalates regulatory uncertainty.
Risks related to legal matters and regulation Our business is subject to substantial regulation. As a global company, we are subject to various state, federal and international laws and regulations…
Added third-party CMO reliance risk and removed diversity/inclusion specificity. Introduces new operational dependency and supply-chain vulnerability.
Our aspirations, goals and disclosures related to sustainability matters expose us to numerous risks, including risks to our reputation. Our Driven to Care sustainability program includes various…
New disclosure of material AI/ML risks: regulatory compliance costs (NIS2, EU AI Act, emerging US state laws), IP infringement exposure, data confidentiality breaches, competitive disadvantage, and operational disruption. Substantive new risk category.
We use machine learning and AI in various business operations, and inability to successfully monitor and manage its use could result in operational, competitive or reputational harm, regulatory…
Substantially expanded disclosure of trade risks. Added specific mechanisms (sanctions, export controls, valuation complexity), supply chain disruption details, reputational harm, anti-U.S. sentiment, and customer/investor hesitation. Escalates from general tariff concern to multi-faceted geopolitical risk.
Changes in trade policies, including the imposition of tariffs, sanctions, and other trade restrictions, may adversely affect our business. The U.S. and other countries in which our products are…
Added specific supply chain risks: tariffs, trade tensions, geopolitical disputes, import/export restrictions, and financial distress of suppliers. Escalates from generic disruption risk to concrete, material threats.
We rely on third parties to provide us with products, materials and services, and are subject to increased labor and material costs and potential disruptions in supply. Labor costs and the materials…
Added explicit AI regulatory risk and cross-border data transfer compliance challenges; expanded scope of data handling risks and regulatory uncertainty.
Our operations and reputation may be impacted if we do not comply with complex and continually evolving laws and regulations regarding data privacy information and the use of AI. We collect, store…
James Saccaro's appointment as Executive Vice President, Chief Financial Officer and Chief Operating Officer effective August 17, 2026 is the principal disclosed action. While the filing also discloses Wetteny Joseph's departure, the appointment of a new CFO/COO at a major public company (Zoetis, a large-cap animal health leader) is the salient event. The compensation details (base salary $1M, LTI target $5M, make-whole awards totaling $7.5M) and his extensive background at GE HealthCare and Baxter underscore the materiality of this executive leadership transition.
View raw filing on EDGAR →Zoetis issued a press release on August 6, 2026, reporting second quarter 2026 financial results (revenue of $2.5 billion, net income of $691 million, diluted EPS of $1.65) and revising full-year 2026 guidance downward for revenue (organic operational growth of -3% to -1%) and adjusted net income (organic operational growth of -9% to -5%). This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, meeting the definition of earnings_release.
View raw filing on EDGAR →Zoetis held its Annual Meeting of Shareholders on May 20, 2026, with voting results on five proposals: election of twelve directors, advisory votes on executive compensation and frequency thereof, ratification of KPMG LLP as independent auditor, and a shareholder proposal on written consent.
View raw filing on EDGAR →